Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets

Virus Research

Volumn 196, Issue , 2015, Pages 56-59

  Lei, Han ^a,b   Peng, Xiaojue ^a   Ouyang, Jiexiu ^a   Zhao, Daxian ^a   Jiao, Huifeng ^a   Shu, Handing ^a   Ge, Xinqi ^a  

^a NANCHANG UNIVERSITY   (China)

^b State University of New York   (United States)

Author keywords

Ferrets; H5N1 virus; Intranasal immunization; L. lactis pgsA HA1

Indexed keywords

BACTERIAL VACCINE; INFLUENZA VACCINE; LACTOCOCCUS LACTIS PSA HA1 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRET; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LACTOCOCCUS LACTIS; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; ANIMAL; BLOOD; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INTRANASAL DRUG ADMINISTRATION; MORTALITY; ORTHOMYXOVIRIDAE INFECTIONS;

AVES; LACTOCOCCUS LACTIS; MUSTELA;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LACTOCOCCUS LACTIS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84920719438     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.11.009     Document Type: Article

References (26)

1. Baz M., Luke C.J., Cheng X., Jin H., Subbarao K. H5N1 vaccines in humans. Virus Res. 2013, 178(1):78-98.
2. Budimir N., de Haan A., Meijerhof T., Gostick E., Price D.A., Huckriede A., Wilschut J. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir. Viruses 2013, 7(6):1202-1209.
3. Chen J.R., Yu Y.H., Tseng Y.C., Chiang W.L., Chiang M.F., Ko Y.A., Chiu Y.K., Ma H.H., Wu C.Y., Jan J.T., Lin K.I., Ma C., Wong C.H. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(7):2476-2481.
4. Easterbrook J.D., Schwartzman L.M., Gao J., Kash J.C., Morens D.M., Couzens L., Wan H., Eichelberger M.C., Taubenberger J.K. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 2012, 432(1):39-44.
5. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(16):1776-1779.
6. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 2006, 194(2):159-167.
7. Gustin K.M., Maines T.R., Belser J.A., van Hoeven N., Lu X., Dong L., Isakova-Sivak I., Chen L.M., Voeten J.T., Heldens J.G., van den Bosch H., Cox N.J., Tumpey T.M., Klimov A.I., Rudenko L., Donis R.O., Katz J.M. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J. Infect Dis. 2011, 204(10):1491-1499.
8. Haaheim L.R., Madhun A.S., Cox R. Pandemic influenza vaccines: the challenges. Viruses 2009, 1(3):1089-1109.
9. Hasegawa H., Ichinohe T., Tamura S., Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev. Vaccines 2007, 6(2):193-201.
10. Lei H., Peng X., Shu H., Zhao D. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus. J. Med. Virol. 2014, 10.1002/jmv.23983.
11. Lei H., Sheng Z., Ding Q., Chen J., Wei X., Lam D.M., Xu Y. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin. Vaccine Immunol. 2011, 18(7):1046-1051.
12. Lei H., Xu Y., Chen J., Wei X., Lam D.M. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 2010, 407(2):319-324.
13. Li J., Jiang Y., Zhao S., Chang X., Liu J., Zeng X., Li Y., Chen H. Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail. Avian Dis. 2012, 56(4 Suppl.):937-939.
14. Lin S.C., Liu W.C., Jan J.T., Wu S.C. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS ONE 2014, 9(3):e92822.
15. Luke C.J., Subbarao K. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev. Vaccines 2014, 13(7):873-883.
16. Mann A.J., Noulin N., Catchpole A., Stittelaar K.J., de Waal L., Veldhuis Kroeze E.J., Hinchcliffe M., Smith A., Montomoli E., Piccirella S., Osterhaus A.D., Knight A., Oxford J.S., Lapini G., Cox R., Lambkin-Williams R. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS ONE 2014, 9(5):e93761.
17. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., Ryan D., Brown L. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 2009, 83(15):7770-7778.
18. Mooney A.J., Li Z., Gabbard J.D., He B., Tompkins S.M. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. 2013, 87(1):363-371.
19. Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 2001, 14(2):430-445.
20. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., Rangarajan B., Newton D.W., Boulton M.L., Monto A.S. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J Med. 2006, 355(24):2513-2522.
21. Rappuoli R., Dormitzer P.R. Influenza: options to improve pandemic preparation. Science 2012, 336(6088):1531-1533.
22. Stohr K., Bucher D., Colgate T., Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol. Biol. 2012, 865:147-162.
23. Vemula S.V., Pandey A., Singh N., Katz J.M., Donis R., Sambhara S., Mittal S.K. Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res. 2013, 178(2):398-403.
24. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 2008, 6(5):349-362.
25. Wood J.M., Levandowski R.A. The influenza vaccine licensing process. Vaccine 2003, 21(16):1786-1788.
26. Zhang J. Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses 2012, 4(11):2711-2735.